Management of RBC-transfusion dependence

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Anemia is a common complication in myelodysplastic syndromes (MDS), significantly impacting patient quality of life.
• Transfusion dependence, while managing symptoms, carries risks like iron overload and increased leukemia transformation.
• The adverse effects of anemia on MDS natural history are increasingly recognized.

Purpose of the Study:

• To review evolving strategies for managing anemia in myelodysplastic syndromes (MDS).
• To highlight the shift from symptom palliation to active treatment following recent FDA approvals.
• To emphasize the importance of considering anemia severity in overall disease management.

Main Methods:

• Literature review of current therapeutic strategies for MDS-associated anemia.
• Analysis of the impact of red blood cell (RBC) transfusion burden on survival outcomes.
• Evaluation of factors influencing therapeutic response and disease progression.

Main Results:

• New FDA-approved therapeutics offer active treatment options beyond RBC transfusions.
• Increased RBC transfusion burden correlates with reduced overall and leukemia-free survival in MDS.
• Effective erythropoiesis restoration may favorably alter the natural history of MDS.

Conclusions:

• Anemia management in MDS has transitioned to active treatment, necessitating careful consideration of patient-specific factors.
• Therapeutic strategies aiming to restore effective erythropoiesis are crucial for improving outcomes.
• Key determinants for selecting primary anemia therapy include age, transfusion burden, EPO levels, and karyotype.